APRE Aprea Therapeutics Inc. Company Short-Term Debt

The prospects for Aprea Therapeutics (APRE) are based on the development of new DNA repair inhibitors to combat resistant lung and ovarian tumors, which bolsters M&A interest amid successful trials. This price chart reflects that the metric stands at 0.00. Drug development is accelerating through academic alliances aimed at restoring cellular defense mechanisms in the therapy of solid neoplasms.

For Aprea Therapeutics (APRE), which is in the R&D stage without a commercial product, the size of short-term liabilities reflects how the pace of clinical trials depends on the availability of immediate liquid capital. This metric aggregates all obligations with a maturity of up to one year, allowing investors to assess the risk of insolvency in the absence of revenue and the company's reliance on external borrowing to sustain development.